NCT07391293

Brief Summary

The aim of this observational study is to define the behavioural and cardiovascular risk factor profiles of patients with genetic aortopathies. The main questions it aims to answer are:

  • How do the interconnections between lifestyle, stress, psychological condition, perception of illness, and state of health influence each other in this population?
  • Beyond traditional risk factors, additional emerging factors should be considered, including pregnancy-related complications, sedentary lifestyle, early menopause and depression. The interplay between eating disorders, lifestyle factors and autoimmune or inflammatory bowel diseases remains poorly understood.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started May 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
May 2025May 2027

Study Start

First participant enrolled

May 6, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 20, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

February 5, 2026

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

February 5, 2026

Status Verified

December 1, 2025

Enrollment Period

1.6 years

First QC Date

January 20, 2026

Last Update Submit

January 29, 2026

Conditions

Keywords

risk stratificationquality of liferare diseasesurvey

Outcome Measures

Primary Outcomes (4)

  • Journey to diagnosis

    The mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.

    15 months

  • Quality of life, functional health and well-being

    The mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.

    15 months

  • Awareness and self-esteem, acceptance of the condition

    The mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.

    15 months

  • psychological and physical well-being

    The mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.

    15 months

Study Arms (1)

TAA

subjects with TAA aged between 14 and 60 years

Other: Journey to diagnosisOther: Quality of life, functional health and well-beingOther: Awareness and self-esteem, acceptance of the conditionOther: psychological and physical well-being

Interventions

questionnaire related to the quality of life and self-care

TAA

questionnaire to describe psychological and physical well-being.

TAA

Questions relating to the course and experience/history of the disease from the onset of symptoms to confirmation of diagnosis; accessibility to referral facilities for treatment and follow-up.

TAA

Eligibility Criteria

Age14 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients with TAA either syndromic or non-syndromic followed at the Cardiovascular Genetic Centre, IRCCS Policlinico San Donato

You may qualify if:

  • signed onformed consent
  • Ability to speak, read and write in Italian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Irccs Policlinico San Donato

Milan, 20097, Italy

RECRUITING

Related Publications (2)

  • Saeyeldin, Ayman A., Camilo A. Velasquez, Syed Usman B. Mahmood, Adam J. Brownstein, Mohammad A. Zafar, Bulat A. Ziganshin, e John A. Elefteriades. 2019. "Thoracic aortic aneurysm: unlocking the "silent killer" secrets". General Thoracic and Cardiovascular Surgery 67(1):1-11.

    BACKGROUND
  • Udugampolage, Nathasha, Rosario Caruso, Mariangela Panetta, Edward Callus, Federica Dellafiore, Arianna Magon, Susan Marelli, e Alessandro Pini. 2021. "Is SF-12 a valid and reliable measurement of health-related quality of life among adults with Marfan syndrome? A confirmatory study". PLoS ONE 16(6 June):e0252864. doi: 10.1371/journal.pone.0252864.

    BACKGROUND

MeSH Terms

Conditions

Aortic Aneurysm, ThoracicRare Diseases

Interventions

Quality of LifeHealth

Condition Hierarchy (Ancestors)

Aortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Health StatusDemographyEpidemiologic MeasurementsPublic HealthEnvironment and Public HealthPopulation Characteristics

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
15 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 20, 2026

First Posted

February 5, 2026

Study Start

May 6, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

May 1, 2027

Last Updated

February 5, 2026

Record last verified: 2025-12

Locations